Previous 10 | Next 10 |
home / stock / bmymp / bmymp news
Prometheus Biosciences has filed to raise $125 million in a U.S IPO. The firm is developing treatments for inflammatory bowel disease conditions. RXDX is in Phase 1 safety trials for its lead candidate for the treatment of ulcerative colitis and Crohn's disease. For further ...
There is growing demand for AI use in drug development. Drug development deals go from $5 million to over $1 billion. Predictive Oncology has a unique platform using real patient samples in its AI process. Predictive Oncology could be undervalued if it can ink large or multipl...
Wedgewood Partners’ 13F portfolio value increased from $632M to $672M this quarter. David Rolfe added Progressive while reducing Tractor Supply. Their top five positions are at 39% of the overall portfolio. For further details see: Tracking David Rolfe's Wedgewood...
David Abrams’ 13F portfolio value increased this quarter from $3.16B to $3.55B. The number of positions decreased from 19 to 17. Abrams Capital Management dropped Franklin Resources and Akebia Therapeutics during the quarter. The top three positions are Lithia Motors, Trans...
Bristol Myers Squibb has an impressive portfolio of assets and strong financials. The company has recently wrapped up large acquisitions. The company is focused on redeveloping its portfolio and expects a massive increase in revenue from new businesses. Going forward, we expect sh...
EDIT has an exclusive patent on the Nobel Prize-winning CRISPR technology that has the potential to change the biotech industry fundamentally. CRISPR is an affordable, clean and effective technology that puts human genes under scientists' full control. If the FDA approves EDIT's l...
Adagene has filed to raise $132 million in a U.S. IPO. The firm is advancing antibody-based treatment candidates for various cancers. ADAG has a capable CEO but the firm is still ultra early stage and the IPO is priced well above the typical range for life science firms. I'll ...
Bristol-Myers Squibb Co (BMY) Q4 2020 Earnings Conference Call February 04, 2021, 10:00 ET Company Participants Timothy Power - VP & Head, IR Giovanni Caforio - Chairman & CEO David Elkins - EVP & CFO Christopher Boerner - EVP & Chief Commercialization Officer Samit Hirawat - ...
On August 25th, 2020, I published an article titled, "Off To The RACES: Natural Gas Equities Outperforming FAANG". The outperformance has continued since that article's publication. Quietly, the leading Appalachia focused natural gas equities, including Range Resources, Antero R...
Bolt Biotherapeutics has filed proposed terms for a $150 million IPO. The firm is developing antibody conjugate treatments for various cancers. BOLT has produced early efficacy results for its lead program and has an impressive investor syndicate, so the IPO is worth consideration...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb $2Pr Company Name:
BMYMP Stock Symbol:
OTCMKTS Market:
Bristol-Myers Squibb $2Pr Website: